.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CA01_Dihydroergotamine.Dihydroergotamine_2

Information

Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.

Pharmacokinetics

Estimated pharmacokinetic parameters for oral administration in adults, since bioavailability is extremely low and no direct population PK model reported.

References

1. Lipton, RB, et al., & Albrecht, D (2025). Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review. Headache 65(3) 527–535. DOI:10.1111/head.14877 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39601088

2. Shrewsbury, SB, et al., & Weinstein, S (2008). Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Current medical research and opinion 24(7) 1977–1985. DOI:10.1185/03007990802160677 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18534051

Revisions

• 06/2025 initial generated model